291 related articles for article (PubMed ID: 25132270)
1. CHK1 overexpression in T-cell acute lymphoblastic leukemia is essential for proliferation and survival by preventing excessive replication stress.
Sarmento LM; Póvoa V; Nascimento R; Real G; Antunes I; Martins LR; Moita C; Alves PM; Abecasis M; Moita LF; Parkhouse RM; Meijerink JP; Barata JT
Oncogene; 2015 Jun; 34(23):2978-90. PubMed ID: 25132270
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia.
Iacobucci I; Di Rorà AG; Falzacappa MV; Agostinelli C; Derenzini E; Ferrari A; Papayannidis C; Lonetti A; Righi S; Imbrogno E; Pomella S; Venturi C; Guadagnuolo V; Cattina F; Ottaviani E; Abbenante MC; Vitale A; Elia L; Russo D; Zinzani PL; Pileri S; Pelicci PG; Martinelli G
J Hematol Oncol; 2015 Nov; 8():125. PubMed ID: 26542114
[TBL] [Abstract][Full Text] [Related]
3. Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells.
Ghelli Luserna Di Rorà A; Ghetti M; Ledda L; Ferrari A; Bocconcelli M; Padella A; Napolitano R; Fontana MC; Liverani C; Imbrogno E; Bochicchio MT; Paganelli M; Robustelli V; Sanogo S; Cerchione C; Fumagalli M; Rondoni M; Imovilli A; Musuraca G; Martinelli G; Simonetti G
Cell Biol Toxicol; 2023 Jun; 39(3):795-811. PubMed ID: 34519926
[TBL] [Abstract][Full Text] [Related]
4. Ultrasound activates ataxia telangiectasia mutated- and rad3-related (ATR)-checkpoint kinase 1 (Chk1) pathway in human leukemia Jurkat cells.
Furusawa Y; Iizumi T; Fujiwara Y; Hassan MA; Tabuchi Y; Nomura T; Kondo T
Ultrason Sonochem; 2012 Nov; 19(6):1246-51. PubMed ID: 22571845
[TBL] [Abstract][Full Text] [Related]
5. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.
Smith J; Tho LM; Xu N; Gillespie DA
Adv Cancer Res; 2010; 108():73-112. PubMed ID: 21034966
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
Massey AJ
Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461
[TBL] [Abstract][Full Text] [Related]
7. The natural anticancer compound rocaglamide selectively inhibits the G1-S-phase transition in cancer cells through the ATM/ATR-mediated Chk1/2 cell cycle checkpoints.
Neumann J; Boerries M; Köhler R; Giaisi M; Krammer PH; Busch H; Li-Weber M
Int J Cancer; 2014 Apr; 134(8):1991-2002. PubMed ID: 24150948
[TBL] [Abstract][Full Text] [Related]
8. CHK1 and replicative stress in T-cell leukemia: Can an irreverent tumor suppressor end up playing the oncogene?
Sarmento LM; Barata JT
Adv Biol Regul; 2016 Jan; 60():115-121. PubMed ID: 26527132
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells.
Ferrao PT; Bukczynska EP; Johnstone RW; McArthur GA
Oncogene; 2012 Mar; 31(13):1661-72. PubMed ID: 21841818
[TBL] [Abstract][Full Text] [Related]
10. Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities.
Sanjiv K; Hagenkort A; Calderón-Montaño JM; Koolmeister T; Reaper PM; Mortusewicz O; Jacques SA; Kuiper RV; Schultz N; Scobie M; Charlton PA; Pollard JR; Berglund UW; Altun M; Helleday T
Cell Rep; 2016 Jan; 14(2):298-309. PubMed ID: 26748709
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the ATR-CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2.
Koppenhafer SL; Goss KL; Terry WW; Gordon DJ
Mol Cancer Res; 2020 Jan; 18(1):91-104. PubMed ID: 31649026
[TBL] [Abstract][Full Text] [Related]
12. Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma.
Baranski Z; Booij TH; Cleton-Jansen AM; Price LS; van de Water B; Bovée JV; Hogendoorn PC; Danen EH
J Pathol; 2015 Jul; 236(3):348-59. PubMed ID: 25757065
[TBL] [Abstract][Full Text] [Related]
13. Differential response of normal and malignant urothelial cells to CHK1 and ATM inhibitors.
Wang WT; Catto JW; Meuth M
Oncogene; 2015 May; 34(22):2887-96. PubMed ID: 25043304
[TBL] [Abstract][Full Text] [Related]
14. Suppression of Tousled-like kinase activity after DNA damage or replication block requires ATM, NBS1 and Chk1.
Krause DR; Jonnalagadda JC; Gatei MH; Sillje HH; Zhou BB; Nigg EA; Khanna K
Oncogene; 2003 Sep; 22(38):5927-37. PubMed ID: 12955071
[TBL] [Abstract][Full Text] [Related]
15. Chk1 is dispensable for G2 arrest in response to sustained DNA damage when the ATM/p53/p21 pathway is functional.
Lossaint G; Besnard E; Fisher D; Piette J; Dulić V
Oncogene; 2011 Oct; 30(41):4261-74. PubMed ID: 21532626
[TBL] [Abstract][Full Text] [Related]
16. PF-00477736 mediates checkpoint kinase 1 signaling pathway and potentiates docetaxel-induced efficacy in xenografts.
Zhang C; Yan Z; Painter CL; Zhang Q; Chen E; Arango ME; Kuszpit K; Zasadny K; Hallin M; Hallin J; Wong A; Buckman D; Sun G; Qiu M; Anderes K; Christensen JG
Clin Cancer Res; 2009 Jul; 15(14):4630-40. PubMed ID: 19584159
[TBL] [Abstract][Full Text] [Related]
17. Rad17 phosphorylation is required for claspin recruitment and Chk1 activation in response to replication stress.
Wang X; Zou L; Lu T; Bao S; Hurov KE; Hittelman WN; Elledge SJ; Li L
Mol Cell; 2006 Aug; 23(3):331-41. PubMed ID: 16885023
[TBL] [Abstract][Full Text] [Related]
18. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
[TBL] [Abstract][Full Text] [Related]
19. ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1.
Zhao H; Piwnica-Worms H
Mol Cell Biol; 2001 Jul; 21(13):4129-39. PubMed ID: 11390642
[TBL] [Abstract][Full Text] [Related]
20. ATR/Chk1/Smurf1 pathway determines cell fate after DNA damage by controlling RhoB abundance.
Wang M; Guo L; Wu Q; Zeng T; Lin Q; Qiao Y; Wang Q; Liu M; Zhang X; Ren L; Zhang S; Pei Y; Yin Z; Ding F; Wang HR
Nat Commun; 2014 Sep; 5():4901. PubMed ID: 25249323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
